Pain-related Fear as a Facilitator of Nocebo Hyperalgesia (LFS)

February 18, 2020 updated by: AWMEvers, Leiden University Medical Center

Pain-related Fear as a Facilitator of Nocebo Hyperalgesia: An Experimental Study

Nocebo hyperalgesia is characterized by adverse pain outcomes, induced by patients' expectations. In the lab, nocebo effects are commonly studied via classical conditioning, a method that employs pairings of neutral cues/treatments with different pain intensities to install differential pain-related expectations. In such conditioning experiments, participants are typically taught that a (sham) treatment exaggerates their pain, by surreptitiously administering high intensity (e.g. pain) stimuli in combination with this treatment. Verbal suggestions are also often used to inform participants of the supposed adverse effects of such treatments. In nocebo studies, higher pain levels and suggestions that are of more threatening nature may induce fear, thereby adding a crucial element to the experimental manipulation. Since nocebo effects are hypothesized to arise in clinical settings due to a combination of several psychological and cognitive mechanisms, it is important to study the role that factors such as higher pain levels, conditioned pain-related fear, or more threatening verbal suggestions may play in the formation of nocebo hyperalgesia. To date, no studies have focused on the fear-inducing effect that different pain intensities or verbal threat suggestions may have and how this fear, in turn, may strengthen the acquisition of nocebo effects. This study aims to investigate whether higher pain intensity or higher pain-related fear induced via threatening suggestions facilitate the acquisition and hinder subsequent extinction of nocebo hyperalgesia. This study will be conducted at Leiden University.

Study Overview

Detailed Description

The investigators expect that higher pain intensity and/or higher pain-related fear induced via threatening suggestions will lead to stronger acquisition of nocebo hyperalgesia and/or more durable nocebo hyperalgesia after extinction.

Main outcome variables:

  • The magnitude of induced nocebo hyperalgesia is defined as the difference in pain ratings for the first nocebo trial compared to the first control trial of the extinction phase.
  • The reduction of nocebo hyperalgesia is defined as the change in reported pain between the first and last nocebo trial of the extinction phase.
  • Fear levels (for mediation analyses) are measured via eye-blink startle modulation and self-reported fear during nocebo trials (relative to control trials).

For EMG analyses this study follows typical pre-processing of EMG recordings, similar to previous studies. The EMG signal will be digitized at 1,000 Hz from 200 ms before the startle probe until 1,500 ms after probe onset. The startle probe is a 100 dBA burst of white noise with instantaneous rise time presented binaurally for 100 ms through earphones. Each 2-4 consecutive startle probe responses of the same cue (nocebo vs control) will be averaged for further analyses. Participants who exhibited a startle response in less than 20% of trials in the first half of induction will be labeled as non-responders. Trials during which, for example, baseline is higher than startle response peak due to an occasional blink before the probe presentation, will be labelled as non-response or reject trials.

  1. Main planned analyses:

    To examine whether higher pain stimulation (high-pain nocebo group) leads to stronger nocebo hyperalgesia, as compared to lower pain stimulation (control nocebo group), a 2x2 mixed model analysis of variance (ANOVA) will be performed with group (high-pain nocebo group, control nocebo group) as the between-subjects factor and trial type as within-subjects factor with two levels (first nocebo extinction trial, first control extinction trial).

  2. Secondary analyses:

2a. To examine whether an impact of higher pain stimulation on the magnitude of nocebo hyperalgesia was mediated by pain-related fear levels, a mediation analysis will be conducted for the high pain nocebo and control nocebo groups, to assess if fear mediates the relationship between pain levels and the magnitude of nocebo hyperalgesia (calculated difference scores between the first nocebo extinction trial and the first control extinction trial).

2b. To examine whether higher pain-related fear induced via a threat suggestion (high-threat nocebo) led to stronger nocebo hyperalgesia, as compared to no threat suggestion (control nocebo group), a 2x2 mixed model ANOVA will be performed with group (high-threat nocebo, control nocebo group) as the between-subjects factor and trial type as within-subjects factor with two levels (first nocebo extinction trial, first control extinction trial).

2c. To examine whether higher pain stimulation (high-pain nocebo group) led to more durable nocebo effect, as compared to lower pain stimulation (control nocebo group), a 2x2 mixed model ANOVA will be performed with group (high-pain nocebo group, control nocebo group) as the between-subjects factor and trial as within-subjects factor with two levels (first nocebo extinction trial, last nocebo extinction trial).

2d. To examine whether an impact of higher pain stimulation on the durability of nocebo hyperalgesia was mediated by pain-related fear levels, a mediation analysis will be conducted to assess if fear mediates the relationship between pain levels and the magnitude of nocebo hyperalgesia after extinction (calculated difference scores between the first nocebo extinction trial and the last nocebo extinction trial).

2e. To examine whether higher pain-related fear induced via a threat suggestion led to more durable nocebo hyperalgesia, as compared to no threat suggestion, a 2x2 mixed model ANOVA will be performed with group (high-threat nocebo, control nocebo group) as the between-subjects factor and trial as within-subjects factor with two levels (first nocebo extinction trial, last nocebo extinction trial).

Study Type

Interventional

Enrollment (Actual)

72

Phase

  • Not Applicable

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

    • South Holland
      • Leiden, South Holland, Netherlands, 2333 AK
        • Leiden University

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

17 years to 35 years (Child, Adult)

Accepts Healthy Volunteers

Yes

Genders Eligible for Study

All

Description

Inclusion Criteria:

  • Aged 17 - 35 years
  • Good understanding of the English language
  • Normal or corrected to normal vision

Exclusion Criteria:

  • Ever having experienced serious medical or psychiatric conditions (e.g., heart or lung disease, panic attacks, drug addiction, clinical depression),
  • Ever having experienced chronic pain complaints (pain for more than 6 months),
  • Experiencing acute physical pain (e.g., headache; above 3 on a 10-point NRS scale), or having used pain medication on the day of testing,
  • Pregnancy or breastfeeding,
  • Having recent injuries to the wrists or arms on the day of testing,
  • Previous participation in this or similar studies (e.g., using conditioning or thermal pain).
  • Having consumed psychotropic medication, recreational drugs, analgesic medication, or more than 3 units of alcohol, in the 24 hours prior to the study appointment.
  • After inclusion, participants who do not reach a sensation of high pain (at least 6 on the NRS) with the highest administered temperature or participants who appear unable to distinguish between moderate and high pain stimuli (reporting at least a mean difference of 1.5 NRS points between nocebo and control trials during induction) will also be excluded.

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Basic Science
  • Allocation: Randomized
  • Interventional Model: Parallel Assignment
  • Masking: Single

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
Experimental: 1. Control nocebo group
Conditioning and extinction of a nocebo response using moderate pain stimuli, nocebo negative suggestions, and no threat suggestions.
Before the start of conditioning, a mock skin-sensitivity test informs participants that their skin reacts to heat normally and it is safe for them to participate. A skin-sensitivity reading shows participants a scale that is in the green (no danger) zone.
During nocebo trials of the acquisition phase, conditioned stimuli (i.e., on-screen visual cues "ON" signaling the activation of sham electrical stimulation) are paired to unconditioned moderate-pain stimuli, to induce a negative association between the activation of electrical stimuli and an increase in pain. During control trials of the acquisition phase, the deactivation of the sham electrical stimulation (i.e., on-screen message "OFF") is paired to 'baseline' pain of lower intensity.
Other Names:
  • Nocebo Induction
During extinction, the previously conditioned nocebo effects on pain are attenuated by pairing the nocebo and control visual cues (i.e., on-screen messages "ON" and "OFF") to pain stimuli of only lower intensity.
Other Names:
  • Nocebo Attenuation
Experimental: 2. High-pain nocebo group
Conditioning and extinction of a nocebo response using higher pain stimuli, nocebo negative suggestions, and no threat suggestions.
Before the start of conditioning, a mock skin-sensitivity test informs participants that their skin reacts to heat normally and it is safe for them to participate. A skin-sensitivity reading shows participants a scale that is in the green (no danger) zone.
During extinction, the previously conditioned nocebo effects on pain are attenuated by pairing the nocebo and control visual cues (i.e., on-screen messages "ON" and "OFF") to pain stimuli of only lower intensity.
Other Names:
  • Nocebo Attenuation
During nocebo trials of the acquisition phase, conditioned stimuli (i.e., on-screen visual cues "ON" signaling the activation of sham electrical stimulation) are paired to unconditioned high-pain stimuli, to induce a negative association between the activation of electrical stimuli and an increase in pain. During control trials of the acquisition phase, the deactivation of the sham electrical stimulation (i.e., on-screen message "OFF") is paired to pain of lower intensity.
Other Names:
  • Nocebo Induction
Experimental: 3. High-threat nocebo
Conditioning and extinction of a nocebo response using moderate pain stimuli, nocebo negative suggestions, and threat suggestions (i.e., fear-inducing suggestions).
During nocebo trials of the acquisition phase, conditioned stimuli (i.e., on-screen visual cues "ON" signaling the activation of sham electrical stimulation) are paired to unconditioned moderate-pain stimuli, to induce a negative association between the activation of electrical stimuli and an increase in pain. During control trials of the acquisition phase, the deactivation of the sham electrical stimulation (i.e., on-screen message "OFF") is paired to 'baseline' pain of lower intensity.
Other Names:
  • Nocebo Induction
During extinction, the previously conditioned nocebo effects on pain are attenuated by pairing the nocebo and control visual cues (i.e., on-screen messages "ON" and "OFF") to pain stimuli of only lower intensity.
Other Names:
  • Nocebo Attenuation
Before the start of conditioning, a mock skin-sensitivity test informs participants that their skin is very sensitive and their nerve fibers are very responsive and they may have adverse reactions to the heat-pain application. A skin-sensitivity reading shows participants a scale that is in the red (higher danger) zone.

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Magnitude of nocebo hyperalgesia
Time Frame: On the testing day, in the first trials of the extinction phase
The magnitude of induced nocebo hyperalgesia is defined as the difference in pain ratings for the first nocebo trial compared to the first control trial of the extinction phase.
On the testing day, in the first trials of the extinction phase

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Reduction of nocebo hyperalgesia
Time Frame: On the testing day, in the extinction phase
The reduction of nocebo hyperalgesia is defined as the change in reported pain between the first and last nocebo trial of the extinction phase.
On the testing day, in the extinction phase

Other Outcome Measures

Outcome Measure
Measure Description
Time Frame
Fear levels
Time Frame: On the testing day, in both experimental phases
Fear levels (for mediation analyses) are measured via eye-blink startle modulation
On the testing day, in both experimental phases
Fear self report levels
Time Frame: On the testing day, in both experimental phases
Fear levels (for mediation analyses) are also measured via self-reported fear during nocebo trials (relative to control trials).
On the testing day, in both experimental phases

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Investigators

  • Principal Investigator: Andrea WM Evers, Leiden University Medical Center

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

October 14, 2019

Primary Completion (Actual)

February 14, 2020

Study Completion (Actual)

February 14, 2020

Study Registration Dates

First Submitted

December 9, 2019

First Submitted That Met QC Criteria

December 11, 2019

First Posted (Actual)

December 12, 2019

Study Record Updates

Last Update Posted (Actual)

February 19, 2020

Last Update Submitted That Met QC Criteria

February 18, 2020

Last Verified

February 1, 2020

More Information

Terms related to this study

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

YES

IPD Plan Description

All data are collected pseudonymised; consent forms are the only sources containing personal data and will not be shared, but are monitored by the department's Data Monitor.

IPD Sharing Time Frame

Data will become available immediately after publication of the study and will be retained for 15 years.

IPD Sharing Access Criteria

Data can be shared with scientists in relevant fields for the purpose of future studies such as replication or meta-analysis (or with designated persons for monitoring purposes).

IPD Sharing Supporting Information Type

  • STUDY_PROTOCOL
  • SAP
  • ANALYTIC_CODE

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Hyperalgesia

Clinical Trials on Threat manipulation (control, no threat)

Subscribe